title: Towards a need to a "biological Sokal risk" in the era of tyrosine kinase inhibitors in choosing front-line therapy in chronic myeloid leukemia.
authors.affiliation: Department of Clinical and Molecular Bio-Medicine, Section of Hematology, Oncology and Clinical Pathology, University of Catania, Italy. fsematol@tiscali.it
authors.forename: Fabio
authors.initials: F
authors.lastname: Stagno
authors.forename: Paolo
authors.initials: P
authors.lastname: Vigneri
authors.forename: Francesco
authors.initials: F
authors.lastname: Di Raimondo
mesh_terms: D016907:Adverse Drug Reaction Reporting Systems / Q000639:trends; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D002755:Choice Behavior; D000069439:Dasatinib; D006301:Health Services Needs and Demand / Q000639:trends*; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D020360:Neoadjuvant Therapy / Q000379:methods*; D047428:Protein Kinase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000009:adverse effects / Q000627:therapeutic use; D012107:Research Design / Q000592:standards / Q000639:trends; D018570:Risk Assessment / Q000379:methods; D012307:Risk Factors; D013844:Thiazoles / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D011505:Protein-Tyrosine Kinases; C498826:nilotinib; D000069439:Dasatinib